Toward a human papillomavirus vaccine

D Rowen, C Lacey

Research output: Contribution to journalArticlepeer-review


Much progress has been made over the past 10 years with regard to development of a vaccine active against HPV. Successful protection has been achieved in animal models using species-specific papillomaviruses; however, HPV diversity may delay the development of successful HPV vaccines, especially those designed as therapeutic vaccines for the treatment of HPV-induced carcinoma and high-grade dysplasia of the cervix. Difficulties arise with regard to assessment of efficacy of potential vaccines. The impetus for long-term studies on vaccine efficacy will initially stem from in vitro evidence of responsiveness to the vaccine. The time when a vaccine will have an impact on the prevalence of high-grade dysplasia and invasive cancer is still some way off.
Original languageEnglish
Pages (from-to)835-8
Number of pages4
JournalDermatologic clinics
Issue number4
Publication statusPublished - 1998


  • Animals
  • Carcinoma, Squamous Cell
  • Condylomata Acuminata
  • Disease Models, Animal
  • Female
  • Genome, Viral
  • Humans
  • Immunization Schedule
  • Male
  • Papillomaviridae
  • Papillomavirus Infections
  • Papillomavirus Vaccines
  • Precancerous Conditions
  • Tumor Virus Infections
  • Uterine Cervical Dysplasia
  • Vaccination
  • Viral Proteins
  • Viral Vaccines

Cite this